However, the use of broader kinase inhibitors such as the first-generation multi-kinase inhibitor midostaurin improved overall survival in younger adult patients in combination with intensive chemotherapy [21], and gilteritinib, which inhibits FLT3-ITD, FLT-TKD, and AXL, was demonstrated to induce durable remissions leading to FDA approval for both drugs in newly diagnosed FLT3 mutant AML and relapsed/refractory AML, respectively. Here, AXL is linked to acute myeloid leukemia.